Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

XRAY vs HOLX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HOLX Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 8–2 Matrix Metrics)

HOLX Overall Winner 6-Pillar Tally: XRAY 2 – 4 HOLX Matrix Metrics: XRAY 2 – 8 HOLX

As of Nov 20, 2026, Hologic Inc (HOLX) is the stronger overall head-to-head candidate over DENTSPLY SIRONA Inc. (XRAY) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). XRAY carries a Unified Composite Score of 42.5/100 (HOLD) at $8.29 (6.8x Forward P/E, 4.7% operating margin), whereas HOLX carries 64.2/100 (BUY) at $76.01 (20.1x Forward P/E, 23.0% operating margin).

  • Technical & Structure Timing Caution: XRAY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.1); meanwhile HOLX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 69.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About XRAY vs HOLX
XRAY NASDAQ
DENTSPLY SIRONA Inc.
Dental Equipment & Supplies
$8.29
-2.36% 1D
Market Cap $1.7B
TTM Revenue $3.58B
Forward P/E 6.8x
Beta / 30D Vol 0.86β · 54% Vol
Unified Composite Score
42.5 / 100 HOLD
Tech 34.0 Fund 53.0 Flow 60.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.7%), weak momentum, RSI 35
RSI-14: 35.1 · SMA20: $9.36 · SMA50: $9.21
HOLX NASDAQ Head-to-Head Winner
Hologic Inc
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
$76.01
+0.48% 1D
Market Cap $16.9B
TTM Revenue $4.13B
Forward P/E 20.1x
Beta / 30D Vol 0.08β · 3% Vol
Unified Composite Score
64.2 / 100 BUY
Tech 75.0 Fund 61.0 Flow 54.0 Mom 49.2
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 69
RSI-14: 69.0 · SMA20: $75.47 · SMA50: $75.29

6-Pillar Scorecard Institutional Category Breakdown (XRAY 2 – 4 HOLX)

Columns: Metric · XRAY · HOLX
1. Valuation Multiples XRAY
Forward P/E 6.8x 20.1x
Trailing P/E 6.6x 31.4x
PEG Ratio 0.66x 1.66x
EV / Revenue 1.1x 4.1x
2. Growth & Scale HOLX
Revenue Growth (YoY) -7.5% +2.5%
Earnings Growth (YoY) +15.2% -9.2%
TTM Revenue (USD) $3.58B $4.13B
Market Cap $1.7B $16.9B
3. Profitability & Quality HOLX
Gross Margin 50.5% 60.4%
Operating Margin 4.7% 23.0%
Net Profit Margin -3.4% 13.2%
Return on Equity (ROE) -8.6% 10.9%
4. Balance Sheet & Cash Flow HOLX
Cash Generation (TTM) $103M $1.35B EBITDA
Cash Flow Margin 2.9% 32.7% EBITDA Mgn
Net Cash / Leverage $2.09B Net Debt (1.69x D/E) $23.51 Book/Sh · 10.9% ROE
Dividend Yield 1.88% None (0.00%)
5. Options & Positioning HOLX
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 26.2% (<1st %ile) 6.3% (3rd %ile)
Put/Call OI Skew 0.24x (Call-Skewed) 6.20x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat XRAY
OpEx & R&D Intensity 45.8% of Rev ($1.64B) 37.4% of Rev ($1.54B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Medical Instruments & Supplies Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: XRAY (2) vs HOLX (8)
Institutional Metric XRAY HOLX Criterion Row Edge
Market Capitalization
Scale
$1.7B $16.9B Larger Scale HOLX
Trailing P/E Ratio
Valuation
6.6x 31.4x Lower Multiple XRAY
Forward P/E Ratio
Valuation
6.8x 20.1x Lower Multiple XRAY
Revenue Growth (YoY)
Growth
-7.5% +2.5% Higher Growth HOLX
Operating Margin (TTM)
Profitability
4.7% 23.0% Higher Margin HOLX
Net Profit Margin
Profitability
-3.4% 13.2% Higher Margin HOLX
Return on Equity (ROE)
Capital Efficiency
-8.6% 10.9% Higher ROE HOLX
52-Week Range Position
Momentum
2% ($8–$15) 100% ($52–$76) Stronger Trend HOLX
Beta / 30D Volatility
Risk Regime
0.86β · 54% Vol 0.08β · 3% Vol Lower Realized Risk HOLX
Unified Institutional Score
Composite Signal
42.5 / 100 (HOLD) 64.2 / 100 (BUY) Higher Composite HOLX
Trailing 12M Revenue (USD)
Operating Scale
$3.58B $4.13B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
50.5% 60.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.66x PEG · 1.1x EV/Rev 1.66x PEG · 4.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$103M ($2.09B Net Debt (1.69x D/E)) $1.35B EBITDA ($23.51 Book/Sh · 10.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon HOLX +13.02 pp
XRAY: -12.68% · HOLX: +0.34%
3M Horizon XRAY +1.34 pp
XRAY: +3.28% · HOLX: +1.94%
6M Horizon XRAY +13.0 pp
XRAY: +15.48% · HOLX: +2.48%
1Y Horizon XRAY +13.0 pp
XRAY: +15.48% · HOLX: +2.48%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XRAY vs HOLX. Trailing 12-month operating profitability (XRAY 4.7% vs HOLX 23.0%) and valuation multiples (XRAY 6.8x vs HOLX 20.1x Forward P/E) are benchmarked directly in Pillar 4 below.

XRAY ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.58B
Gross Margin50.5%
Op. Margin4.7%
ROE / Fwd P/E-8.6% · 6.8x
HOLX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.13B
Gross Margin60.4%
Op. Margin23.0%
ROE / Fwd P/E10.9% · 20.1x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
XRAY BREAKDOWN
77d in phase · OBV DISTRIBUTION
Current IV 26.2%
IV Percentile <1st %ile
Put/Call OI Skew 0.24x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact XRAY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
HOLX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 6.3%
IV Percentile 3rd %ile
Put/Call OI Skew 6.20x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact HOLX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
XRAY Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $1.7B market capitalization and 4.7% operating margin.
OpEx & R&D Reinvestment 45.8% of Rev ($1.64B)
90D Engineering Disclosures 0 Published
HOLX Moat Profile Scale & Operating Efficiency Moat
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $16.9B market capitalization and 23.0% operating margin.
OpEx & R&D Reinvestment 37.4% of Rev ($1.54B)
90D Engineering Disclosures 0 Published

Investor FAQ XRAY vs HOLX Key Questions & Quantitative Answers

As of Nov 20, 2026, Hologic Inc (HOLX) is the stronger overall head-to-head candidate over DENTSPLY SIRONA Inc. (XRAY) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). XRAY carries a Unified Composite Score of 42.5/100 (HOLD) at $8.29 (6.8x Forward P/E, 4.7% operating margin), whereas HOLX carries 64.2/100 (BUY) at $76.01 (20.1x Forward P/E, 23.0% operating margin). Technical & Structure Timing Caution: XRAY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.1); meanwhile HOLX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 69.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

HOLX leads the Growth & Scale pillar: XRAY posts -7.5% YoY revenue growth and +15.2% YoY earnings growth on $3.58B TTM revenue (50.5% gross margin, 4.7% operating margin), compared with HOLX at +2.5% YoY revenue growth and -9.2% YoY earnings growth on $4.13B TTM revenue (60.4% gross margin, 23.0% operating margin). On trailing 12-month operating scale, XRAY generates $3.58B in USD-normalized revenue versus $4.13B for HOLX. In operating R&D and SG&A reinvestment, XRAY deploys 45.8% of Rev ($1.64B) (0 90-day corporate R&D disclosures) versus 37.4% of Rev ($1.54B) (0 disclosures) for HOLX.

XRAY screens cheaper on headline valuation multiples. XRAY trades at 6.8x Forward P/E, 6.6x Trailing P/E, 0.66x PEG, and 1.1x EV/Revenue (2.9% FCF margin), whereas HOLX trades at 20.1x Forward P/E, 31.4x Trailing P/E, 1.66x PEG, and 4.1x EV/Revenue (32.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XRAY (-8.6% ROE) versus HOLX (10.9% ROE) capital efficiency.

In options market volatility and institutional positioning, XRAY carries 26.2% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.24x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.86β · 54% Vol realized risk). By comparison, HOLX carries 6.3% implied volatility (3rd %ile, Compressed (<25th %ile)), a 6.20x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.08β · 3% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.